CAS 1239908-20-3
:Ixazomib citrate
Description:
Ixazomib citrate is a small molecule proteasome inhibitor primarily used in the treatment of multiple myeloma. It is characterized by its ability to disrupt the proteasome's function, leading to the accumulation of regulatory proteins that promote apoptosis in cancer cells. The compound is administered orally, which provides a convenient route of administration compared to traditional intravenous therapies. Ixazomib citrate is often used in combination with other agents, such as lenalidomide and dexamethasone, to enhance therapeutic efficacy. Its mechanism of action involves the inhibition of the 26S proteasome, a complex responsible for degrading ubiquitinated proteins, thereby affecting various cellular processes, including cell cycle regulation and apoptosis. The substance has undergone extensive clinical trials, demonstrating its effectiveness and safety profile in patients with relapsed or refractory multiple myeloma. Additionally, Ixazomib citrate is notable for its favorable pharmacokinetic properties, including a manageable side effect profile, which contributes to its role in modern cancer therapy.
Formula:C20H23BCl2N2O9
InChI:InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)/t14-/m0/s1
InChI key:InChIKey=MBOMYENWWXQSNW-AWEZNQCLSA-N
SMILES:C(C(O)=O)C1(CC(O)=O)OB([C@@H](NC(CNC(=O)C2=C(Cl)C=CC(Cl)=C2)=O)CC(C)C)OC1=O
Synonyms:- IXAZOMIB CITRATE
- MLN 9708
- 2-[(1R)-1-[[2-[(2,5-Dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acid
- 2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid
- Ixazomib citrate
- IXAZOMIB
- 2-[4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolan-4-yl]acetic acid
- (R)-2,2′-(2-(1-(2-(2,5-Dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid
- (R)-2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid
- 1,3,2-Dioxaborolane-4,4-diacetic acid, 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-
- 2-[(1R)-1-[[2-[(2,5-Dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acid
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 9 products.
1,3,2-Dioxaborolane-4,4-diacetic acid, 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-
CAS:Formula:C20H23BCl2N2O9Purity:97%Color and Shape:SolidMolecular weight:517.1216(R)-2,2'-(2-(1-(2-(2,5-Dichlorobenzamido)Acetamido)-3-Methylbutyl)-5-Oxo-1,3,2-Dioxaborolane-4,4-Diyl)Diacetic Acid
CAS:<p>(R)-2,2'-(2-(1-(2-(2,5-Dichlorobenzamido)Acetamido)-3-Methylbutyl)-5-Oxo-1,3,2-Dioxaborolane-4,4-Diyl)Diacetic Acid</p>Purity:98%Molecular weight:517.12g/molIxazomib citrate
CAS:<p>Ixazomib citrate (MLN9708), a prodrug of Ixazomib (MMLN-2238), is an oral 2nd-gen proteasome inhibitor with anti-cancer potential (IC50: 3.4 nM).</p>Formula:C20H23BCl2N2O9Purity:98.37% - >99.99%Color and Shape:SolidMolecular weight:517.12Ixazomibe citrate
CAS:<p>Proteosome inhibitor; antineoplastic</p>Formula:C14H19BCl2N2O4Purity:Min. 95%Molecular weight:361.03 g/mol







